Overall survival
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Koh Fukushi, Hiroshi Imaoka, Masafumi Ikeda, Junki Mizusawa, Chigusa Morizane, Takuji Okusaka, Satoshi Kobayashi, Naoki Sasahira, Satoshi Shimizu, Kentaro Yamazaki, Naohiro Okano, Haruo Miwa, Kazuo Hara, Sohei Satoi, Keiji Sano, Kenji Sakai, Rie Sugimoto, Kazuyoshi Nakamura, Takeshi Terashima, Masato Ozaka, Makoto Ueno, JCOG Hepatobiliary and Pancreatic Oncology Group
Jpn J Clin Oncol 55(4) 355-361
BACKGROUND: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer. METHODS: The objective of this post-hoc analysis was to assess the inter-institutional heterogeneity in the overall survival and progression-free survival of patients with advanced biliary tract cancer treated with first-line chemotherapy in the JCOG1113 trial. The heterogeneity in the overall survival and progression-free survival was assessed according to three factors: hospital volume, experience in medical oncology and experience in biliary intervention. A total of 300 advanced biliary tract cancer patients were analyzed. There were no statistically significant trends observed between hospital volume, experience in medical oncology, or experience in biliary intervention and overall survival (hospital volume: adjusted trend P value = 0.6796; experience in medical oncology: adjusted trend P value = 0.4092; experience in biliary intervention: adjusted trend P value = 0.6112). Similarly, no statistically significant trends were observed between these factors and progression-free survival (hospital volume: adjusted trend P value = 0.3000; experience in medical oncology: adjusted trend P value = 0.1108; experience in biliary intervention: adjusted trend P value = 0.2898). CONCLUSIONS: This study revealed no inter-institutional heterogeneity in the overall survival and progression-free survival in the JCOG1113 study population of advanced biliary tract cancer patients.
1 个 Figure · 2 个 KM 面板
Kaplan–Meier curves for both overall survival (OS) (A) and progression-free survival (PFS) (B) in eligible advanced biliary tract cancer (BTC) patients treated with GS or GC.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。